[Clinical study of a new antivitamin K: 6134 M.D. 3-(alpha-acetonylbenzyl) 4-hydroxycoumarin dimethylaminoethanol].
D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D001167:Arteritis / Q000188:drug therapy; D001281:Atrial Fibrillation / Q000188:drug therapy; D001282:Atrial Flutter / Q000188:drug therapy; D001779:Blood Coagulation Factors / Q000032:analysis; D001780:Blood Coagulation Tests; D002986:Clinical Trials as Topic; D005169:Factor VIII / Q000032:analysis; D005260:Female; D006331:Heart Diseases / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy; D009205:Myocarditis / Q000188:drug therapy; D011516:Prothrombin / Q000032:analysis; D013916:Thrombelastography; D013923:Thromboembolism / Q000188:drug therapy; D013997:Time Factors; D014812:Vitamin K / Q000037:antagonists & inhibitors*
D000925:Anticoagulants; D001779:Blood Coagulation Factors; D014812:Vitamin K; D011516:Prothrombin; D005169:Factor VIII
Etude clinique d'un nouvel antivitamine K: le 6134 M.D. 3(alpha-acétonylbenzyl) 4-hydroxycoumarine diméthylaminoéthanol.